Literature DB >> 27121152

BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.

Ann E Walts1, Kenzo Hiroshima2, Stephanie M McGregor3, Di Wu2, Aliya N Husain3, Alberto M Marchevsky1.   

Abstract

BACKGROUND: Loss of BAP1 by immunohistochemistry (IHC) and CDKN2A(p16) deletion by fluorescence in situ hybridization (FISH) have been proposed to distinguish malignant mesothelioma (MM) from atypical reactive mesothelial proliferations (ARMP) in effusions but it is uncertain whether both tests are needed routinely.
METHODS: Paraffin embedded blocks from 67 effusions (32 MM, 35 ARMP) were evaluated with BAP1 IHC. 38 of them (17 MM, 21 ARMP) were also analyzed with CDKN2A (p16) FISH. Criteria for MM were absence of BAP1 nuclear staining in >50% of atypical mesothelial cells in the presence of a positive internal control, and/or CDKN2A(p16) homozygous or hemizygous deletion pattern in >15% or >41.5% of atypical mesothelial cells, respectively. Sensitivity (SS), specificity (SP), positive, and negative predictive values (PPV, NPV) for MM were calculated.
RESULTS: 17 of 32 MM were correctly diagnosed by IHC (SS 53.1%, SP 85.7%, PPV 77.3%, NPV 64.3% for MM). In the subset of 38 cases studied by IHC and FISH, the SS, SP, PPV, and NPV of IHC for MM were 41.2, 81.0, 63.6, and 63.0%, respectively. 7 of 17 MM were diagnosed by FISH (SS 41.2%, SP 100%, PPV 100%, NPV 67.7% for MM).
CONCLUSION: BAP1 IHC and CDKN2A(p16) FISH yield similar sensitivities for MM in paired samples but FISH has a higher specificity. To diagnose effusions with atypical mesothelial cells, use of both tests is optimal. However, BAP1 IHC alone may be sufficient to diagnose MM when clinical, imaging, and cytological findings strongly suggest MM. Diagn. Cytopathol. 2016.
© 2016 Wiley Periodicals, Inc. Diagn. Cytopathol. 2016;44:599-606. © 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  BAP1; CDKN2A (p16) FISH; effusion; malignant mesothelioma

Mesh:

Substances:

Year:  2016        PMID: 27121152     DOI: 10.1002/dc.23491

Source DB:  PubMed          Journal:  Diagn Cytopathol        ISSN: 1097-0339            Impact factor:   1.582


  10 in total

1.  Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.

Authors:  Jing Liu; Xuanzhi Liao; Yingying Gu; Lin Fu; Jin Zhao; Longguang Li; Zhucheng Chen; Juhong Jiang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 3.  Pleural mesothelioma classification update.

Authors:  Mary Beth Beasley; Francoise Galateau-Salle; Sanja Dacic
Journal:  Virchows Arch       Date:  2021-01-21       Impact factor: 4.064

4.  Utility of Survivin, BAP1, and Ki-67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia.

Authors:  Kei Kushitani; Vishwa Jeet Amatya; Amany Sayed Mawas; Rui Suzuki; Yoshihiro Miyata; Morihito Okada; Kouki Inai; Takumi Kishimoto; Yukio Takeshima
Journal:  Oncol Lett       Date:  2018-01-10       Impact factor: 2.967

5.  Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis.

Authors:  Li-Ming Wang; Zhen-Wang Shi; Ji-Ling Wang; Zhi Lv; Fang-Bin Du; Qing-Bin Yang; Yong Wang
Journal:  Oncotarget       Date:  2017-08-17

6.  Malignant pleural mesothelioma and mesothelial hyperplasia: A new molecular tool for the differential diagnosis.

Authors:  Rossella Bruno; Greta Alì; Riccardo Giannini; Agnese Proietti; Marco Lucchi; Antonio Chella; Franca Melfi; Alfredo Mussi; Gabriella Fontanini
Journal:  Oncotarget       Date:  2017-01-10

7.  Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

Authors:  Sanjeevan Muruganandan; Helman Alfonso; Peter Franklin; Keith Shilkin; Amanda Segal; Nola Olsen; Alison Reid; Nick de Klerk; Aw Bill Musk; Fraser Brims
Journal:  Br J Cancer       Date:  2017-02-14       Impact factor: 7.640

Review 8.  Molecular testing on serous effusion: An update.

Authors:  Saumya Sahu; Parikshaa Gupta; Pranab Dey
Journal:  Cytojournal       Date:  2021-12-06       Impact factor: 2.091

Review 9.  Lymphoproliferative disorder involving body fluid: diagnostic approaches and roles of ancillary studies.

Authors:  Jiwon Koh; Sun Ah Shin; Ji Ae Lee; Yoon Kyung Jeon
Journal:  J Pathol Transl Med       Date:  2022-07-04

Review 10.  Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.

Authors:  David B Chapel; Jefree J Schulte; Aliya N Husain; Thomas Krausz
Journal:  Transl Lung Cancer Res       Date:  2020-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.